Effects of two oral contraceptives on plasma levels of nitric oxide, homocysteine, and lipid metabolism

Metabolism: Clinical and Experimental

Volumn 51, Issue 9, 2002, Pages 1216-1221

  Merki Feld, Gabriele S ^a   Imthurn, Bruno ^a   Keller, Paul J ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LIPID; NITRIC OXIDE; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL;

ADULT; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; ARTICLE; ATHEROSCLEROSIS; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DATA ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; METABOLIC REGULATION; NORMAL HUMAN; ORAL CONTRACEPTION; PILL; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM;

EID: 0036737770     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2002.34038     Document Type: Article

References (65)

1. Boushey CJ, Beresford SA, Omenn GS, et al: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274:1049-1057, 1995
2. Den Heijer M, Koster T, Blom HJ, et al: Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759-762, 1996
3. Graham IM, Daly LE, Refsum HM, et al: Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 277:1775-1781, 1997
4. Prasad K: Homocysteine, a risk factor for cardiovascular disease. Int J Angiol 8:76-86, 1999
5. Okamura T, Kitamuta A, Moriyama Y, et al: Plasma level of homocysteine is correlated to extracranial carotid-artery atherosclerosis in non-hypertensive Japanese. J Cardiovasc Risk 6:371-377, 1999
6. Tonstad S, Hjermann I: Cardiovascular risk factors and testing of relatives amongst patients with familial hyperlipidaemia one decade after a clinical trial. J Intern Med 248:111-118, 2000
7. Rassoul F, Richter V, Janke C, et al: Plasma homocysteine and lipoprotein profile in patients with peripheral arterial occlusive disease. Angiology 51:189-196, 2000
8. Sydow K, Boger RH: Homocyst(e)in, endotheliale Dysfunktion und kardiovaskulaeres Risiko. Pathomechanismen und therapeutische Optionen. Z Kardiol 90:1-11, 2001
9. Böger RH, Sydow K, Borlak J, et al: LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: Involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 87:99-105, 2000
10. Böger RH, Bode-Boger SM, Sydow K, et al: Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 20:1557-1564, 2000
11. Böger RH, Lentz SR, Bode-Böger SM, et al: Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci 100:161-167, 2001
12. Vallance P, Hingorani A: Endothelial nitric oxide in humans in health and disease. Int J Exp Pathol 80:291-303, 1999
13. Cooke JP, Tsao PS: Is NO an endogenous antiatherogenic molecule? Arterioscler Thromb 14:653-655, 1994
14. Chowienczyk PJ, Watts GF, Cockcroft JR, et al: Sex differences in endothelial function in normal and hypercholesterolaemic subjects. Lancet 344:305-306, 1994
15. Calver A, Collier J, Moncada S, et al: Effect of loca intraarterial NG-monomethyl-L-arginine in patients with hypertension: The nitric oxide dilator mechanism appears abnormal. J Hypertens 10:1025-1031, 1992
16. Celermajer DS, Sorensen KE, Georgakopoulos D, et al: Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 88:2149-2155, 1993
17. Woo KS, Chook P, Lolin YI, et al: Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 96:2542-2544, 1997
18. Boers GH, Smals AG, Trijbels FJ, et al: Unique efficiency of methionine metabolism in premenopausal women may protect against vascular disease in the reproductive years. J Clin Invest 72:1971-1976, 1983
19. Wouters MG, Moorrees MT, van der Mooren MJ, et al: Plasma homocysteine and menopausal status. Eur J Clin Invest 25:801-805, 1995
20. Mijatovic V, Kenemans P, Netelenbos C, et al: Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril 69:876-828, 1998
21. van Baal WM, Smolders RG, van der Mooren MJ, et al: Hormone replacement therapy and plasma homocysteine levels. Obstet Gynecol 94:485-491, 1999
22. Imthurn B, Rosselli M, Jaeger AW, et al: Differential effects of hormone-replacement therapy on endogenous nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol valerate and cyproterone acetate or medroxyprogesterone acetate. J Clin Endocrinol Metab 82:388-394, 1997
23. Cicinelli E, Ignarro LJ, Matteo MG, et al: Effects of estrogen replacement therapy on plasma levels of nitric oxide in postmenopausal women. Am J Obstet Gynecol 180:334-339, 1999
24. Mendelsohn ME, Karas RH: The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801-1811, 1999
25. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Acute myocardial infarction and combined oral contraceptives: Results of an international multicentre case-control study. Lancet 349:1202-1209, 1997
26. Lewis MA, Heinemann LA, Spitzer WO, et al: The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 56:129-140, 1997
27. Mant J, Painter R, Vessey M: Risk of myocardial infarction, angina and stroke in users of oral contraceptives: An updated analysis of a cohort study. Br J Obstet Gynaecol 105:890-896, 1998
28. Rosenberg L, Kaufman DW, Helmrich SP, et al: Myocardial infarction and cigarette smoking in women younger than 50 years of age. JAMA 253:2965-2969, 1985
29. Croft P, Hannaford P: Risk factors for acute myocardial infarction in women. BMJ 298:674, 1989 (letter)
30. Dunn N, Thorogood M, Faragher B, et al: Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 318:1579-1583, 1999
31. Consensus Conference on Combination Oral Contraceptives and Cardiovascular Disease. Fertil Steril 71:1S-6S, 1999 (suppl)
32. Kleinert H, Wallerath T, Euchenhofer C, et al: Estrogens increase transcription of the human endothelial NO synthase gene: Analysis of the transcription factors involved. Hypertension 31:582-588, 1998
33. Nygard O, Vollset SE, Refsum H, et al: Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 274:1526-1533, 1995
34. Welch GN, Loscalzo J: Homocysteine and atherothrombosis. N Engl J Med 338: 1042-1050, 1998
35. Landmesser U, Hornig B, Drexler H: Endothelial dysfunction in hypercholesterolemia: mechanisms, pathophysiological importance, and therapeutic interventions. Semin Thromb Hemost 26:529-537, 2000
36. Tretjakovs P, Kalnins U, Dabina I, et al: Plasma HDL-cholesterol has an effect on nitric oxide production and arachidonic acid metabolism in the platelet membranes of coronary heart disease patients without LDL-hypercholesterolemia. Med Sci Monit 6:507-511, 2000
37. Warnholtz A, Mollnau H, Oelze M, et al: Antioxidants and endothelial dysfunction in hyperlipidemia. Curr Hypertens Rep 3:53-60, 2001
38. Gevers Leuven JA, Dersjant-Roorda MC, Helmerhorst FM, et al: Estrogenic effect of gestodene- or desogestrel-containing oral contraceptives on lipoprotein metabolism. Am J Obstet Gynecol 163:358-362, 1990
39. Kuhl H, Marz W, Jung-Hoffmann C, et al: Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives. Am J Obstet Gynecol 163:363-369, 1990
40. Kloosterboer HJ, Rekers H: Effects of three combined oral contraceptive preparations containing desogestrel plus ethinyl estradiol on lipid metabolism in comparison with two levonorgestrel preparations. Am J Obstet Gynecol 163:370-373, 1990
41. Hishikawa K, Nakaki T, Marumo T, et al: Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett 360:291-293, 1995
42. Zancan V, Santagati S, Bolego C, et al: 17Beta-estradiol decreases nitric oxide synthase II synthesis in vascular smooth muscle cells. Endocrinology 140:2004-2009, 1999
43. Fleming I, Busse R: NO: The primary EDRF. J Mol Cell Cardiol 31:5-14, 1999
44. Merki-Feld GS, Imthurn B, Keller PJ: The effect of the menstrual cycle and of ethinylestradiol on nitric oxide, endothelin-1 and homocysteine plasma levels. Horm Metab Res 32:288-293, 2000
45. Detmers PA, Hernandez M, Mudgett J, et al: Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol 165:3430-3435, 2000
46. Steegers-Theunissen RP, Boers GH, Steegers EA, et al: Effects of sub-50 oral contraceptives on homocysteine metabolism: A preliminary study. Contraception 45:129-139, 1992
47. Green TJ, Houghton LA, Donovan U, et al: Oral contraceptives did not affect biochemical folate indexes and homocysteine concentrations in adolescent females. J Am Diet Assoc 98:49-55, 1998
48. Brattstrom L, Israelsson B, Olsson A, et al: Plasma homocysteine in women on oral oestrogen-containing contraceptives and in men with oestrogen-treated prostatic carcinoma. Scand J Clin Lab Invest 52:283-287, 1992
49. Lentz SR, Sobey CG, Piegors DJ, et al: Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 98:24-29, 1996
50. Tawakol A, Omland T, Gerhard M, et al: Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 95:1119-1121, 1997
51. Woo KS, Chook P, Lolin YI, et al: Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 96:2542-2544, 1997
52. Lentz SR: Homocysteine and vascular dysfunction. Life Sci. 61:1205-1215, 1997
53. Stamler JS, Osborne JA, Jaraki O, et al: Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 91:308-318, 1993
54. Chow K, Cheung F, Lao TT, et al: Effect of homocysteine on the production of nitric oxide in endothelial cells. Clin Exp Pharmacol Physiol 26:817-818, 1999
55. De Groot PG, Willems C, Boers GH, et al: Endothelial cell dysfunction in homocystinuria. Eur J Clin Invest 13:405-410, 1983
56. Vane JR, Anggard EE, Botting RM: Regulatory functions of the vascular endothelium. N Engl J Med 323:27-36, 1990
57. Warnholtz A, Mollnau H, Oelze M, et al: Antioxidants and endothelial dysfunction in hyperlipidemia. Curr Hypertens Rep 3:53-60, 2001
58. Landmesser U, Hornig B, Drexler H: Endothelial dysfunction in hypercholesterolemia: Mechanisms, pathophysiological importance, and therapeutic interventions. Semin Thromb Hemost 26:529-537, 2000
59. Real JT, Chaves FJ, Martinez-Uso I, et al: Importance of HDL cholesterol levels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia. Eur Heart J 22:465-471, 2001
60. Badimon JJ, Badimon L, Fuster V: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 85:1234-1241, 1990
61. Plump AS, Scott CJ, Breslow JL: Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 91:9607-9611, 1994
62. Miller GJ, Miller NE: Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1:16-19, 1975
63. Navab M, Hama SY, Cooke CJ, et al: Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Step 1. J Lipid Res 41:1481-1494, 2000
64. Theilmeier G, De-Geest B, Van Veldhoven PP, et al: HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice. FASEB J 14:2032-2039, 2000
65. Jakubowski H, Zhang L, Bardeguez A, et al. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: Implication for atherosclerosis. Circ Res 87:45-51, 2000